Key facts
as of Sep 2026- It has raised $16.5M; the latest was Later Stage VC in Feb 2026.
- Notable investors include Alexandria Venture Investments, Investissement Quebec, Fonds de solidarite FTQ, Amplitude Ventures, Amzak Health — 8 tracked in total.
- 1 institutional filer reports fund marks on Thryv Therapeutics across 2 filings.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Thryv Therapeutics
- ·The full record, as it builds
Recorded secondary trades
No secondary trades in Thryv Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
1 filers · latest Apr 20261 SEC-registered fund reported 2 fair-value marks on Thryv Therapeutics between Jan 2026 and Apr 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
No funding rounds for Thryv Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Thryv Therapeutics
Operator of a precision medicine company intended to develop novel therapeutics to treat Long QT Syndrome and other arrhythmias. The company pioneers a precision medicine approach to treat genetic and drug-induced long QT syndrome, atrial fibrillation, and treatment-resistant cancers with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase, enabling the healthcare industry to access therapies that will reduce the risk of sudden cardiac death and improve the quality of life for patients with these conditions.
- Sector
- Healthcare
- HQ
- Montreal, Canada
- Founded
- 2019
- Employees
- 31
- Website
- thryvtrx.com/
- Ownership
- Privately Held (backing)